Clario and CellCarta team on histopathology sample management system
Clario and CellCarta have teamed up to create a tissue sample management system for clinical trials.
In a joint statement released last week, the firms said the aim is to streamline the handling of tissue and samples by providing trial sites with several to submit pathology data/samples, including fixed tissue, tissue blocks, glass slides or whole slide images.
Clario's web-based 21 CFR Part 11 compliant sample management platform will play a pivotal role in the new system.
The project will also leverage CellCarta's standard operating procedures – through which samples are processed and digitized in a consistent manner using certified equipment.
The idea is to increase the number of sites that could potentially participate in pathology-related trials by removing the limitations surrounding the availability of local histopathology support staff or equipment.
Joyce Suhy, executive vice president, Medical Imaging and Specialty Solutions at Clario, said "This collaboration brings together Clario's cutting-edge scientific expertise and unrivaled clinical trial endpoint solutions with CellCarta's unparalleled sample processing and management expertise.
"This partnership advances Clario's ability to support histopathology studies, providing our customers with full visibility for biopsy sample logistics and significantly accelerates delivery of centralized assessments for eligibility and efficacy endpoints."
The firms also suggested that customers would warm to a single-vendor solution for sample management, the automated transfer of digitized pathology images and accelerated centralized assessments.
The deal – described as a strategic partnership – fits with the business expansion through collaboration strategy Clario has followed in recent years.
In July, for example, the tech firm teamed with medical technology company Sleepiz AG to set up sponsor-driven partnership to integrate novel sleep and respiratory parameters into clinical trials.
And, in August, Clario expanded an agreement with personal electrocardiogram developer AliveCor, with the aim being to “enable trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes.”
DepositPhotos/Elnur_